Division of Pharmaceutical Sciences

Faculty

Christopher K Surratt, Ph.D. Division Head of Pharmaceutical Sciences Professor of Pharmacology 411 Mellon T 412.396.5007 F 412.396.4660 surratt@duq.edu

Educational and Professional Background

B.A. (Chemistry)-- University of Virginia
Ph.D. (Chemistry)-- University of Virginia
Postdoctoral Fellow, University of California, Berkeley
Senior Staff Fellow, National Institute on Drug Abuse, NIH
Assistant Professor, Albert Einstein College of Medicine

Courses Currently Taught

• PHBM 352: Foundations of Pharmacology and Medicinal Chemistry (Coursemaster)
• PHSL 477W: Service Learning Experience in Pharmacy
• GPSC 513: Principles of Drug Action, Design and Delivery
• GPSC 572: Methods of Evaluation of Drug Action and Toxicity

Right click on the link to download the file for the:
2012 NBDOA High School.ppt
Right click on the link to download the file for the:
2012 NBDOA High School Notes.pdf
Right click on the link to download the file for the:
2012 NBDOA Middle School.ppt
Right click on the link to download the file for the:
2012 NBDOA Middle School.pdf

Active Grants

• R01DA026530 National Institute on Drug Abuse (NIDA) NIH Grant
  Principal Investigator: C. K. Surratt, Ph.D.
  Co-investigators: J. D. Madura, Ph.D. and D. J. Lapinsky, Ph.D.
  “Dopamine Transporter Structure and Function”
  $627,250
  7/1/09 – 6/30/12
• R01DA027806 NIDA NIH/NSF Grant
  Principal Investigator: J. D. Madura, Ph.D.
  Co-investigators: C. K. Surratt, Ph.D. and D. J. Lapinsky, Ph.D.
  “CRCNS: Computational and Experimental Study of Dopamine and Serotonin Transporters”
  $1,545,450
  7/1/09 – 6/30/14

Research Interests

• Structure-function studies on the plasma membrane monoamine (dopamine, norepinephrine and serotonin) transporter (MAT) proteins are the primary research focus. Computer molecular modeling-guided site-directed mutagenesis of transporter amino acid residues and molecular pharmacology of the obtained mutant transporters are employed in elucidating binding sites for abused psychostimulants (e.g., cocaine, amphetamine), antidepressants and other CNS drugs. The molecular models are also used in virtual screening of small molecule structural libraries in search of novel MAT ligands. Such ligands are then tested as candidate “lead compound” therapeutics for a variety of CNS disorders. Our molecular pharmacology lab works closely with computational chemists, medicinal chemists, biophysical chemists and behavioral neuropharmacologists at Duquesne University, University of Pittsburgh, NIH and several other research institutes.

Publications

• Nolan, T.L., Lapinsky, D.J., Talbot, J.N., Indarte, M., Liu, Y., Manepalli, S., Geffert, L.M., Amos, M.E., Taylor, P.N., Madura, J.D. and Surratt, C.K. (2011). Identification of a novel selective serotonin reuptake inhibitor by coupling monoamine transporter-based virtual screening and rational molecular hybridization. ACS Chem. Neurosci., 2, 544-52.
• Manepalli, S., Geffert, L.M., Surratt, C.K. and Madura, J.D. (2011). Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore. J. Chem. Inf. Model. 51, 2417-26.
• Lapinsky, D.J., Aggarwal, S., Nolan, T.L., Surratt, C.K., Lever, J.R., Acharya, R., Vaughan, R.A., Pandhare, A. and Blanton, M.P.: (±)-2-(N-tert-butylamino)-3'-[125I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban). Bioorg. Med. Chem. Lett., published online 11/24/11 (PMID: 22119468).
• Surratt, C.K., Wildfong, P.L.D. and Kamal, K. (2010). Research funding expectations as a function of faculty teaching/administrative workload. Res. Soc. Admin. Pharmacy, published online 7/23/10 (DOI:10.1016/j.sapharm.2010.04.006).
• Van Amburgh, J.A., Surratt, C.K., Green, J., Gallucci, R.M., Colbert, J., Zatopek, S.L. and Blouin, R.A. (2010). Succession planning in U.S. pharmacy schools. Am. J. Pharm. Educ. 74, Article 86 (online).
• Indarte, M., Liu, Y., Madura, J.D. and Surratt, C.K. (2010). Receptor-based discovery of a plasmalemmal monoamine transporter inhibitor via high-throughput docking and pharmacophore modeling. ACS Chem. Neurosci. 1, 223-33.
• Gedeon, P., Indarte, M., Surratt, C.K. and Madura, J.D. (2010). Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer. Proteins 78, 797-811.
• Lapinsky, D.J., Aggarwal, S., Huang, Y., Surratt, C.K., Lever, J.R., Foster, J.D. and Vaughan, R.A. (2009). A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. Bioorg. Med. Chem. 17, 3770-4.
• Indarte, M., Madura, J.D. and Surratt, C.K. (2008). Dopamine transporter comparative molecular modeling and binding site prediction using the LeuTAa leucine transporter as a template. Proteins. 70, 1033-46. (Published online 9/10/07.)
• Surratt, C.K. and Desselle, S.P. (2007). Pharmacy students’ perception of a teaching evaluation process. Am. J. Pharm. Educ., 71, Article 06 (online).
• Ukairo, O.T., Ramanujapuram, S. and Surratt, C.K. (2007). Fluctuation of the dopamine uptake inhibition potency of cocaine, but not amphetamine, in mammalian cells expressing the dopamine transporter. Brain Res., 1131, 68-76.
• Surratt, C.K., Witt-Enderby, P.A., Johnson, D.A., Anderson, C.A., Bricker, J.D., Davis, V.L., Firestine, S.M. and Meng, W.S. (2006). Development of a neuroscience oriented "methods" course for graduate students of pharmacology and toxicology. Cell Biol. Educ. 5, 188-96.
• Surratt, C.K. (2006). Creation of a graduate oral/written communication skills course. Am. J. Pharm. Educ., 70(1):Article 05, 1-8
• Surratt, C.K., Ukairo, O.T. and Ramanujapuram, S. (2005). Recognition of psychostimulants, antidepressants and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters. Am. Assoc. Pharmaceu. Sci. J. 7:Article 74, E739-51.
• Surratt, C.K., Drennen, J.K. III and Bricker, J.D. (2005). The "research track" concentration, a new PharmD student elective option. Am. J. Pharm. Educ., 69(5):Article 90, 1-6.
• Desselle, S.P., Surratt, C.K., Astle, J., White, L.A., Yacovelli, L., Barnhisel, G., Jewell, M., Shippen, H. and Holmes, E.R. (2005). Evolution of a required service-learning course: lessons learned and plans for the future. J. Pharm. Teach, 12:23-40.
• Ukairo, O.T., Bondi, C.D., Newman, A.H., Kulkarni, S.S., Kozikowski, A.P., Pan, S. and Surratt, C.K. (2005). Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classic dopamine uptake inhibitors cocaine, methylphenidate and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J. Pharmacol. Exp. Ther., 314:575-83.
• Surratt, C.K. and Adams, W.R. (2005). G protein-coupled receptor structural motifs and their application to opioid receptor activation. Curr. Top. Med. Chem. 5:315-24.
• Surratt, C.K. and Desselle, S.P. (2004). "The Neuroscience Behind Drugs of Abuse", a PharmD service-learning project. Am. J. Pharm. Educ. 68(4):Article 99, 1-8.
• Surratt, C.K. (2004). Increasing the PharmD student's interest in a required neuropharmacology course. Am. J. Pharm. Educ. 68(2):Article 33, 1-5.
• Wang, W., Sonders, M.S., Ukairo, O., Scott, H., Kloetzel, M.N. and Surratt, C.K. (2003). Dissociation of cocaine high affinity binding and dopamine uptake inhibition at the dopamine transporter. Mol. Pharmacol. 64:430-9.
• Spivak, C.E., Beglan, C.L., Zollner, C. and Surratt, C.K. (2003). ß-Funaltrexamine, a gauge for the recognition site of wild-type and mutant H297Q mu opioid receptors. Synapse 49:55-60.
• Zöllner, C., Johnson, P.S., Wang, J.B., Roy Jr., A.J., Layton, K.M., Wu, J.M. and Surratt, C.K. (2000). Control of mu opioid receptor expression by modification of cDNA 5'- and 3'-noncoding regions. Brain Res. Mol. Brain Res. 79(1-2):159-62.
• Wang, D., Surratt, C.K. and Sadee, W. (2000). Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu opioid receptor in morphine-pretreated cells. J. Neurochem. 75(2):763-71.
• Deng, H.B., Yu, Y., Pak, Y., O'Dowd, B.F., George, S.R., Surratt, C.K., Uhl, G.R. and Wang, J.B. (2000). Role for the C-terminus in agonist-induced mu opioid receptor phosphorylation and desensitization. Biochemistry 39(18):5492-9.
• Zhang, P., Johnson, P.S., Zöllner, C., Wang, W., Wang, Z., Montes, A.E., Seidleck, B.K., Blaschak, C.J. and Surratt, C.K. (1999). Mutation of human mu opioid receptor extracellular "disulfide cysteine residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Brain Res. Mol. Brain Res. 72(2):195-204.
• Makman, M.H., Dobrenis, K. and Surratt, C.K. (1998). Properties of mu-3 opiate alkaloid receptors in macrophages, astrocytes, and HL-60 human promyelocytic leukemia cells. Adv. Exp. Med. Biol. 437:137-48.
• Spivak, C.E., Beglan, C.L., Seidleck, B.K., Hirshbein, L.D., Blaschak, C.J., Uhl, G.R. and Surratt, C.K. (1997). Naloxone activation of mu opioid receptors mutated at a histidine residue lining the opioid binding cavity. Mol. Pharmacol. 52(6):983-92.
• Wang, J.B. and Surratt, C.K. (1997). Molecular cloning and characterization of receptors for drugs of abuse. In: Drug Addiction and its Treatment: Nexus of Neuroscience and Behavior, eds. Johnson, B.A. and Roache, J., Lippincott Raven Publishers, Philadelphia, pp. 295-317.
• Uhl, G.R., Miner, L., Donovan, D., Sharpe, L., Johnson, P.S., Moriwaki, A., Wang, J.B. and Surratt, C.K. (1995). Mu opiate receptor: expression, transgenic mice, and influences of C-terminal and 3'-untranslated regions. Analgesia 1: 801.
• Surratt, C.K., Johnson, P.S., Moriwaki, A., Seidleck, B.K., Blaschak, C.J., Wang, J.B., Yuhasz, S. and Uhl, G.R. (1994). mu opiate receptor structure/function relationships. Regulatory Peptides 54: 289.
• Surratt, C.K., Johnson, P.S., Moriwaki, A., Seidleck, B.K., Blaschak, C.J., Wang, J.B. and Uhl, G.R. (1994). mu opiate receptor: charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J. Biol. Chem. 269: 20548.
• Surratt, C.K., Wang, J.B., Yuhasz, S., Amzel, L.M., Kwon, H.M., Handler, J.S. and Uhl, G.R. (1993). Sodium- and chloride-dependent transporters in brain, kidney, and gut: lessons from complementary DNA cloning and structure-function studies. Current Opinion in Nephrology and Hypertension 2: 744.
• Persico, A.M., Schindler, C.W., Brannock, M.T., Gonzalez, A.M., Surratt, C.K. and Uhl, G.R. (1993). Dopaminergic gene expression during amphetamine withdrawal. NeuroReport 4: 41-4.
• Surratt, C.K., Persico, A.M., Yang, X.-D., Edgar, S.R., Bird, G.S., Hawkins, A.L., Griffin, C.A., Li, X., Jabs, E.W. and Uhl, G.R. (1993). A human synaptic vesicle monoamine transporter cDNA predicts post-translational modifications, reveals chromosome 10 gene localization and identifies Taq I RFLPs. FEBS Letters 318: 325.
• Surratt, C.K., Milan, S.C. and Chamberlin, M.J. (1991). Spontaneous cleavage of RNA in ternary complexes of Escherichia coli RNA polymerase and its significance for the mechanism of transcription. Proc. Natl. Acad. Sci. USA 88: 7983.
• Surratt, C.K., Carter, B.J., Payne, R.C. and Hecht, S.M. (1990). Metal ion and substrate structure dependence of the processing of tRNA precursors by RNase P and M1 RNA. J. Biol. Chem. 265: 22513.
• Surratt, C.K., Lesnikowski, Z., Schifman, A.L., Schmidt, F.J. and Hecht, S.M. (1990). Construction and processing of transfer RNA precursor models. J. Biol. Chem. 265: 22506.
• Roesser, J.R., Xu, C., Payne, R.C., Surratt, C.K. and Hecht, S.M. (1989). Preparation of misacylated aminoacyl-tRNAPhe 's useful as probes of the ribosomal acceptor site. Biochemistry 28: 5185.
• Surratt, C.K., Carter, B.J. and Hecht, S.M. (1988). Processing of a synthetic tRNA precursor model by E. coli RNase P and M1 RNA. In: Molecular Biology of RNA 94: 79. UCLA Symposia on Molecular and Cellular Biology, New Series, ed. Cech, T.R., Allan R. Liss Inc., New York, N.Y.
• Carter, B.J., Surratt, C.K. and Hecht, S.M. (1988). Chemical processing of synthetic and natural tRNA precursors. FASEB J. 2: 4261.
• Surratt, C.K., Carter, B.J. and Hecht, S.M. (1988). Synthetic "tRNA dimers": A novel approach to the study of transfer RNA biosynthesis. J. Cellular Biochem. 12D: 208.